Log In
BCIQ
Print this Print this
 

XmAb13551 (formerly CD3 x CD38)

  Manage Alerts
Collapse Summary General Information
Company Xencor Inc.
DescriptionBispecific antibodies against CD3 and CD38
Molecular Target CD3 ; CD38
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,745.0M

$45.0M

$1,700.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/16/2015

$1,745.0M

$45.0M

$1,700.0M

Get a free BioCentury trial today